Casgevy access in Pakistan: the DRAP named-patient pathway
How Pakistani families access Casgevy (exagamglogene autotemcel) for severe sickle cell disease and transfusion-dependent beta-thalassemia through the DRAP Special Permission route and qualified Authorized Treatment Centers abroad.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Ask about Casgevy in Pakistan
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Patients in Pakistan access Casgevy (exa-cel) for sickle cell disease and transfusion-dependent beta thalassemia through the DRAP named-patient mechanism, filed by a PMDC-licensed physician for a specific named patient. Because Casgevy requires REMS-certified administration, the realistic path often combines named-patient sourcing with coordinated travel; Reserve Meds handles US sourcing, logistics, and timeline planning end to end.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Casgevy reaches patients in Pakistan
Casgevy (exagamglogene autotemcel, exa-cel, the first FDA-approved CRISPR-Cas9 gene-edited autologous cell therapy, FDA-approved December 2023 for sickle cell disease and January 2024 for transfusion-dependent beta-thalassemia in patients 12 years and older) is not visible on the DRAP registered-product verification portal at dra.gov.pk/e-services/online-data-verification as of 2026-05-31. Pakistan does not currently host a Vertex Pharmaceuticals authorised treatment centre (ATC), so Casgevy access for Pakistani patients runs through a hybrid route: travel-to-treatment at an authorised ATC abroad (UK NHS at Manchester Royal Infirmary, KSA at King Faisal Specialist Hospital and Research Centre, UAE at Abu Dhabi Stem Cells Center, or US Vertex-authorised ATCs) combined with DRAP coordination for the apheresis-collection-to-infusion timeline. Where any component is imported into Pakistan (for instance, a cryopreserved cell product for institutional administration), the Special Permission for Institutional Import of Unregistered Therapeutic Goods under the Drugs Act 1976 applies, filed through dra.gov.pk/therapeutic-goods/import-export/special-permissions. The Casgevy-specific clinical justification must document: confirmed homozygous or compound heterozygous sickle cell genotype or transfusion-dependent beta-thalassemia, age 12 years or older, and HLA-matched related allogeneic stem cell transplant unavailable or inappropriate per the FDA label. Conditioning regimen (busulfan-based myeloablation) and post-infusion long-term follow-up commitments must be coordinated with the receiving ATC. DRAP processing for institutional import is several working days when documentation is complete.
Where Casgevy infusion patients are seen in Pakistan
Because Casgevy infusion happens at an authorised ATC abroad, the Pakistani role is haematology workup, eligibility confirmation, post-infusion surveillance, and long-term follow-up.
What Casgevy costs in Pakistan
This is a one-time cost rather than an annualised cost, but it does not include the apheresis, myeloablative conditioning, transplant admission, and ICU-capacity-equivalent post-infusion support. Medicine price: quote on request. You get a written quote for your case before you commit. State Bank of Pakistan outward remittance is the binding constraint for staging payments.
Funding and access barriers for Casgevy in Pakistan
Demand for curative gene therapy is large but funding remains the binding constraint. Public-sector funding for Casgevy at any scale is not observed as of 2026-05-31. Medicine price: quote on request. Every case gets a written custom quote before you commit. Major private insurers do not list gene therapy on standard retail policies and have not published an unlicensed-drug formulary inclusive of Casgevy; named-individual catastrophic-illness riders on corporate group policies are theoretically capable but no Pakistani Casgevy claim adjudicated by a private insurer is publicly documented. Out-of-pocket plus diaspora-family contribution is the only documented funding pattern. The DRAP institutional-import permit step is procedurally straightforward; the binding barrier is funding, not regulation.
Recent regulatory and access news for Casgevy
Vertex Pharmaceuticals continued the global ATC network expansion through 2025 with public additions in the UK (NHS England 7 commissioned centres), Saudi Arabia (KFSHRC, Riyadh), and UAE (Abu Dhabi Stem Cells Center); the live ATC roster is published at casgevy.com. Medicine price: quote on request. You get a written quote for your case before you commit. No DRAP-specific bulletin on Casgevy or gene therapy class has been observed over the last 12 months. The DRAP Federal Cabinet exemption for the import of unregistered drugs in defined public-interest cases (under Section 23 of the Drugs Act 1976, reported mid-2025 at Express Tribune) may apply procedurally to cell-therapy components routed through institutional import.
Operational timeline for a Pakistani Casgevy case
We give you a written timeline estimate for your case before you commit. The phases break down as follows. Phase 1 (weeks 1 to 4): clinical eligibility confirmation by the Pakistani haematology service, genotype documentation, donor-search workup completion to confirm allogeneic HSCT unavailability or inappropriateness, ATC selection and acceptance of the named patient, and family financial scoping. Phase 2 (weeks 4 to 8): documentation packaging, DRAP institutional-import filing where applicable, ATC intake paperwork, State Bank of Pakistan outward-remittance preparation, and travel-and-visa preparation for the patient plus one or two caregivers. Phase 3 (weeks 8 to 12): apheresis collection at the ATC, transition to the manufacturing window, and bridging supportive care including transfusion management for thalassaemia patients or vaso-occlusive crisis management for SCD patients. Phase 4 (weeks 12 to 20): Vertex manufacturing window. Phase 5 (weeks 20 to 24): myeloablative conditioning with busulfan-based regimen, Casgevy infusion, engraftment monitoring, and acute post-infusion care. Phase 6 (weeks 24 to 28 and beyond): post-engraftment monitoring at the ATC with progressive transition to outpatient care, eventual return to Pakistan, and long-term follow-up at the Pakistani referring haematology service.
Documentation set for the case
The composite Casgevy case documentation set includes the prescription naming the specific patient with the Casgevy single-administration plan, the clinical justification letter from the treating Pakistani haematologist covering diagnosis confirmation by genotype, severity assessment (transfusion burden for TDT, vaso-occlusive crisis frequency and end-organ status for SCD), prior therapies and their outcomes, donor-search documentation, and the rationale for autologous gene-edited therapy over allogeneic HSCT; the Pakistani prescriber's PMDC licence verification; the receiving ATC's Vertex-qualified status letter and acceptance of the named patient; the apheresis facility and manufacturing chain-of-custody plan from collection through cryopreservation, transport, and dosing; the institutional import permit application under the Drugs Act 1976 if any component touches Pakistani territory; the financial readiness attestation, since the case is cash-pay or sponsor-funded; and the long-term follow-up commitment, since Vertex requires up to 15 years of follow-up data on every Casgevy patient. Reserve Meds packages the kit, the prescribing haematologist signs the clinical components, and a registered Pakistani importer or the receiving ATC's overseas-coordination office files the import-side documentation.
Operational risk register
Four risks recur across Pakistani gene-therapy cases. The first is funding execution. Medicine price: quote on request. You get a written quote for your case before you commit. The State Bank of Pakistan outward-remittance approval process for sums of this magnitude is the binding execution constraint and is sequenced into the case at the start, not at the manufacturing window. The second is disease progression during the case, particularly for SCD patients with high vaso-occlusive crisis frequency. The bridging plan with the local haematologist is set